Drug Trial Radar · NCT02278341
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
838
Actual
Start
Nov 21, 2014
Primary completion
Jun 8, 2017
Study completion Jul 6, 2018
Sponsor
- Lead sponsor
- Astellas Pharma Europe B.V.Astellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Kyntra Bio
- First posted
- Oct 30, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was conducted to explore a new therapy for anemia in participants with end stage renal disease (ESRD) on dialysis. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin (which contains iron) is important for the transport of oxygen in your blood. The purpose of this study was to evaluate if roxadustat is effective and safe in the maintenance treatment of anemia in ESRD participants on stable dialysis. Roxadustat was compared to epoetin alfa and darbepoetin alfa, commercially available medicines for treatment of anemia.
Conditions
- Anemia
- End Stage Renal Disease (ESRD)
Interventions
RoxadustatDrug
Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
Epoetin alfaDrug
Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.
Darbepoetin alfaDrug
Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.
IronDrug
Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was \< 100 ng/mL (\< 220 pmol/L) or TSAT \< 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)]Time frame: Baseline and weeks 28 to 36
- Change From BL to the Average Hb in Weeks 28 to 52 Regardless of Rescue Therapy [US (FDA)]Time frame: Baseline and weeks 28 to 52
Locations
143 sites in 17 countries. Site status is shown where the registry gives one.
Site BE32001
Aalst, Belgium
Site BE32019
Antwerp, Belgium
Site BE32002
Antwerp, Belgium
Site BE32012
Baudour, Belgium
Site BE32017
Bonheiden, Belgium
Site BE32003
Leuven, Belgium
Site BE32013
Liège, Belgium
Site BE32011
Roeselare, Belgium
Site BE32004
Brussels, Flemish Brabant, Belgium
Site BG35925
Blagoevgrad, Bulgaria
Site BG35931
Haskovo, Bulgaria
Site BG35915
Pleven, Bulgaria
Site BG35909
Plovdiv, Bulgaria
Site BG35919
Plovdiv, Bulgaria
Site BG35920
Rousse, Bulgaria
Site BG35938
Shumen, Bulgaria
Site BG35924
Sofia, Bulgaria
Site BG35906
Sofia, Bulgaria
Site BG35921
Sofia, Bulgaria
Site BG35907
Stara Zagora, Bulgaria
Site BG35916
Varna, Bulgaria
Site BG35918
Varna, Bulgaria
Site BG35903
Veliko Tarnovo, Bulgaria
Site BG35937
Yambol, Bulgaria
Site HR38508
Čakovec, Croatia
Site HR38505
Karlovac, Croatia
Site HR38507
Osijek, Croatia
Site HR38506
Rijeka, Croatia
Site HR38504
Slavonski Brod, Croatia
Site HR38501
Zadar, Croatia
Site HR38509
Zagreb, City of Zagreb, Croatia
Site CZ42008
Liberec, Czechia
Site CZ42021
Prague, Czechia
Site CZ42015
Rakovník, Czechia
Site FR33005
Amiens, France
Site FR33010
La Tronche, France
Site FR33007
Saint Priez En Jarez, France
Site FR33055
Saint-Ouen, France
Site FR33056
Valenciennes, France
Site GE99503
Tbilisi, Georgia
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.